Publications
Publications
Show Results For
- All HBS Web
(9,246)
- Faculty Publications (1,611)
- March 2007
- Teaching Note
Latvia: Economic Strategy after EU Accession (TN)
By: Michael E. Porter and Christian H.M. Ketels
Teaching note to 707515. View Details
- March 2007 (Revised August 2009)
- Case
Aurolab: Bringing First-World Technology to the Third-World Blind
Aurolab is the in-house producer of IOLs (required in cataract surgery) for the Aravind Eye Care System, a group of charity hospitals with the largest volume of eye surgery in the world. Aurolab's manufacturing capability and capacity had long exceeded the requirements... View Details
- February 2007 (Revised November 2007)
- Case
Latvia: Economic Strategy after EU Accession
By: Michael E. Porter and Christian H.M. Ketels
Describes the economic development of Latvia, a small eastern European country on the shores of the Baltic Sea, from regaining independence in 1991 to European Union (EU) accession in 2004 and is set on May 1st, 2004, the day Latvia became an EU member. Latvia had... View Details
- January 2007 (Revised December 2007)
- Case
PSI: Social Marketing Clean Water
By: V. Kasturi Rangan, Nava Ashraf and Marie Bell
Senior management at PSI, arguably the world's largest and most successful social marketer with impressive achievements in the field of family planning, HIV/AIDS, and malaria prevention must determine what to do about their slow-to-take-off clean water initiative.... View Details
- December 2006 (Revised March 2008)
- Case
The European Union in the 21st Century
Focuses on the challenges facing the European Union in 2006. Following the French and Dutch referendums in 2005, the fate of the European Constitution is in jeopardy. Ten new accession countries have just joined the EU, with Turkey in the beginning stages of the... View Details
- October 2006 (Revised August 2007)
- Case
Calloway Laboratory: Pee for Profit
By: Richard G. Hamermesh and David Kiron
Describes the formation and rapid growth of a drug-testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. View Details
- September 2006 (Revised April 2007)
- Case
Medtronic Vision 2010
Describes the company's year-long efforts to transition from a medical device company selling products to physicians for use with patients suffering chronic end-stage disease, to a medical technology company providing life-long solutions for people with chronic... View Details
- September 2006 (Revised December 2006)
- Case
Arizona Department of Public Health: The Challenges of Preparing for a Public Health Emergency
By: Lynda M. Applegate, Ajay Vinze, T. S. Raghu and Minu Ipe
In the post-9/11 era information technology enablement for emergency preparedness and response have taken on increased significance. Public health organizations like ADHS play a critical role in any statewide preparation for large scale emergencies. With issues like... View Details
- September 2006
- Article
The Speed of Learning in Noisy Games: Partial Reinforcement and the Sustainability of Cooperation
By: Yoella Bereby-Meyer and Alvin E. Roth
In an experiment, players ability to learn to cooperate in the repeated prisoners dilemma was substantially diminished when the payoffs were noisy, even though players could monitor one anothers past actions perfectly. In contrast, in one-time play against a succession... View Details
- August 2006 (Revised September 2006)
- Case
Scopie's Enlarged Gland Shrinker
Describes a firm that markets a laser for a fictional problem. Asks readers to evaluate Scopie's marketing and production strategy (it plans to start in India and then expand to the United States) and its long-term viability. View Details
- April 2006 (Revised April 2007)
- Case
Endeca Technologies: New Growth Opportunities
By: Paul A. Gompers and Kristin Perry
Steve Papa, CEO of Endeca Technologies, must decide whether to expand into a new market with a new application of his company's technology. Endeca has experienced significant success with its information access software in the online retail industry, and in September... View Details
- March 2006 (Revised November 2010)
- Background Note
Protecting Foreign Investors
Describes the emergence of several kinds of efforts to assure the safety of foreign investment in emerging markets: international arbitration, expanded official political risk insurance, credit from government agencies, and intervention by investors' home governments.... View Details
- March 2006 (Revised November 2006)
- Case
The Market and the Mountain Kingdom: Change in Lesotho's Textile Industry
By: Rawi E. Abdelal, Regina M. Abrami, Noel Maurer and Aldo Musacchio
In Maseru, the capital of the Kingdom of Lesotho, the stirrings of industrialization and modernization were promising, and more than 50,000 workers, mostly women, were employed in the textile sector; the figure reflected more than a threefold increase in just a few... View Details
Keywords: History; Labor Unions; Trade; Business and Stakeholder Relations; Financial Crisis; Globalized Markets and Industries; Business and Government Relations; Decision Choices and Conditions; Foreign Direct Investment; Developing Countries and Economies; Fashion Industry; Apparel and Accessories Industry; Lesotho
- January 2006 (Revised May 2007)
- Case
Endo Pharmaceuticals (A): From LBO to...?
By: Richard G. Hamermesh and Brian DeLacey
Endo Pharmaceuticals was formed in 1997 as a leveraged buyout spin-off from DuPont Merck. In 1999, it must decide whether to do an IPO or merge with a smaller company. View Details
- January 2006 (Revised April 2007)
- Case
General Electric Healthcare, 2006
By: Tarun Khanna and Elizabeth Raabe
In January 2006, Joe Hogan, head of General Electric (GE) Healthcare Technologies, prepared to step into William Castell's shoes as CEO of GE Healthcare, the world's leading manufacturer of diagnostic imaging equipment. In 2004, former CEO Jeff Immelt acquired Amersham... View Details
Keywords: Corporate Entrepreneurship; Cost vs Benefits; Growth and Development Strategy; Mergers and Acquisitions; Machinery and Machining; Global Range; Multinational Firms and Management; Product Design; Technological Innovation; Expansion; Value Creation; Business Subsidiaries; Health Industry; Medical Devices and Supplies Industry
- December 2005 (Revised October 2013)
- Case
Fred Khosravi and AccessClosure (A)
By: Richard Hamermesh and Liz Kind
Fred Khosravi is a serial medical device entrepreneur. In his latest venture, he must decide whether to sell now or continue to develop his current product and whether to market it, sell the company, or IPO. View Details
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details
- November 2005 (Revised December 2005)
- Case
County Department of Public Health: Organizing for Emergency Preparedness and Response
By: Lynda M. Applegate, Ajay Vinze and Minu Ipe
The anthrax attacks of 2001 exposed serious inadequacies in the response of the U.S. public health system to meet such grave threats. The public health infrastructure required rebuilding to respond to any type of large-scale health emergency. The Public Health... View Details
- November 2005 (Revised July 2009)
- Case
Cutter & Buck (A)
By: William A. Sahlman and Victoria Winston
Only three short months into her new position as CEO of publicly traded golf apparel manufacturer Cutter & Buck, Fran Conley discovers accounting irregularities that call into question the reliability of this company's financial statements. Working closely with her... View Details
- November 2005 (Revised November 2005)
- Case
Massachusetts General Hospital and the Enbrel Royalty
By: David S. Scharfstein and Darren R. Smart
Massachusetts General Hospital is considering selling its royalty interest in Enbrel, Amgen's blockbuster drug for the treatment of rheumatoid arthritis. In assessing whether to sell, and at what price, the hospital must determine its value to a potential buyer as well... View Details